On April 25, 2022, Richard J. Wanstall, Chief Financial Officer, principal financial officer and principal accounting officer of Aileron Therapeutics, Inc., notified the Company of his resignation, effective May 6, 2022, to pursue another career opportunity. Mr. Wanstall's resignation was not the result of any disagreement with the Company on any matter relating to its operations, policies or practices.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.19 USD | -0.31% | -6.45% | +4.64% |
05-16 | Aileron Therapeutics, Inc. Announces Chief Financial Officer Changes | CI |
05-16 | Aileron Therapeutics, Inc. Announces Executive Changes | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+4.64% | 66.17M | |
+16.73% | 123B | |
+13.04% | 107B | |
-5.80% | 24.01B | |
+2.21% | 22.59B | |
-10.09% | 18.16B | |
-40.52% | 16.84B | |
-14.00% | 16.23B | |
+1.18% | 13.43B | |
+24.18% | 11.32B |
- Stock Market
- Equities
- ALRN Stock
- News Aileron Therapeutics, Inc.
- Aileron Therapeutics, Inc. Announces Resignation of Richard J. Wanstall as Chief Financial Officer, Effective from May 6, 2022